These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37063886)

  • 1. Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
    Chen H; Yang W; Ji Z
    Front Immunol; 2023; 14():1171420. PubMed ID: 37063886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 4. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA.
    He Z; Gu J; Luan T; Li H; Li C; Chen Z; Luo E; Wang J; Huang Y; Ding M
    Front Immunol; 2022; 13():973974. PubMed ID: 36211333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
    Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
    Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
    Yan T; Zhou W; Li C
    Int Urol Nephrol; 2024 Nov; 56(11):3447-3462. PubMed ID: 38789872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer.
    Zhou M; Zhang Z; Bao S; Hou P; Yan C; Su J; Sun J
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32382761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
    Yao Y; Wang J; Yang F; Gao W
    Front Immunol; 2022; 13():924498. PubMed ID: 35844536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
    Ma X; Wei X; Yang G; Li S; Liu R
    Comb Chem High Throughput Screen; 2024; 27(8):1205-1221. PubMed ID: 37653625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.
    Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
    Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
    Ma L; Chen H; Yang W; Ji Z
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
    Front Immunol; 2022; 13():898493. PubMed ID: 35812369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study.
    Li J; Kong Z; Qi Y; Wang W; Su Q; Huang W; Zhang Z; Li S; Du E
    Int J Surg; 2024 Aug; 110(8):4911-4931. PubMed ID: 38759695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
    Xie T; Peng S; Liu S; Zheng M; Diao W; Ding M; Fu Y; Guo H; Zhao W; Zhuang J
    Mol Cancer; 2024 Feb; 23(1):30. PubMed ID: 38341586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
    Wan Z; Wang Y; Li C; Zheng D
    Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.